Wave II clinical study will evaluate THRV-1268, Thryv’s oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...

MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Prioritizing nonpharmacologic strategies, enhancing staff training, and distinguishing Delirium Superimposed on Dementia (DSD) are vital to improving outcomes for hospitalized patients with Alzheimer ...

Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a ...

Detailed price information for Aytu Biopharma Inc (AYTU-Q) from The Globe and Mail including charting and trades.

Energy drinks may promise instant energy, but their high caffeine and stimulant content can place serious strain on the heart ...

NDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home ...

Professor Ibrahim Adeola Katibi, a renowned cardiologist, teaches at the University of Ilorin in Kwara State. He is a former ...

Introduction The increasing incidence of type 2 diabetes mellitus (T2DM) among women of reproductive age poses significant health risks for both mothers and their fetuses. Optimising blood glucose ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj ® (revumenib) ...

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 inhibitors at community clinics.